Martin Capital Partners LLC Boosts Stock Position in Cencora, Inc. (NYSE:COR)

Martin Capital Partners LLC boosted its holdings in shares of Cencora, Inc. (NYSE:COR) by 31.6% during the 1st quarter, Holdings Channel.com reports. The firm owned 1,240 shares of the company’s stock after purchasing an additional 298 shares during the quarter. Martin Capital Partners LLC’s holdings in Cencora were worth $345,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of COR. JFS Wealth Advisors LLC increased its holdings in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after purchasing an additional 46 shares during the last quarter. Banque Transatlantique SA purchased a new stake in Cencora during the 4th quarter worth approximately $29,000. SBI Securities Co. Ltd. purchased a new stake in Cencora during the 4th quarter worth approximately $30,000. Kentucky Trust Co purchased a new stake in Cencora during the 4th quarter worth approximately $33,000. Finally, WASHINGTON TRUST Co increased its holdings in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after purchasing an additional 46 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the transaction, the chairman now owns 315,913 shares of the company’s stock, valued at approximately $89,027,442.53. This represents a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the transaction, the executive vice president now directly owns 14,665 shares of the company’s stock, valued at approximately $3,934,326.20. The trade was a 21.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,253 shares of company stock worth $10,582,297 in the last 90 days. 10.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. UBS Group boosted their price target on Cencora from $298.00 to $335.00 and gave the company a “buy” rating in a report on Tuesday, April 29th. Wells Fargo & Company upgraded Cencora from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $274.00 to $337.00 in a report on Tuesday, June 3rd. Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. Bank of America boosted their price target on Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Friday, April 11th. Finally, Citigroup boosted their price target on Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $306.91.

Cencora Trading Up 0.1%

NYSE:COR opened at $284.32 on Wednesday. Cencora, Inc. has a 12-month low of $218.65 and a 12-month high of $309.35. The firm has a market capitalization of $55.11 billion, a P/E ratio of 40.44, a P/E/G ratio of 1.31 and a beta of 0.58. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The business has a 50 day simple moving average of $286.28 and a 200 day simple moving average of $260.81.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The business had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. During the same quarter in the previous year, the firm posted $3.80 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were given a dividend of $0.55 per share. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.77%. Cencora’s dividend payout ratio is currently 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.